960157-89-5

Basic information

• Product Name: (S)-5-methyl-N-[2-(4-nitrophenyl)-1-(2-phenylthiazol-4-yl)ethyl]-1,3,4-thiadiazol-2-amine
• Synonyms: (S)-5-methyl-N-[2-(4-nitrophenyl)-1-(2-phenylthiazol-4-yl)ethyl]-1,3,4-thiadiazol-2-amine
• CAS NO: 960157-89-5
• Molecular Weight: 423.519
• Mol File: 960157-89-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (S)-5-methyl-N-[2-(4-nitrophenyl)-1-(2-phenylthiazol-4-yl)ethyl]-1,3,4-thiadiazol-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-5-methyl-N-[2-(4-nitrophenyl)-1-(2-phenylthiazol-4-yl)ethyl]-1,3,4-thiadiazol-2-amine(960157-89-5)
• EPA Substance Registry System: (S)-5-methyl-N-[2-(4-nitrophenyl)-1-(2-phenylthiazol-4-yl)ethyl]-1,3,4-thiadiazol-2-amine(960157-89-5)

Safety Data

• Hazardous Substances Data: 960157-89-5(Hazardous Substances Data)

Upstream product

• 960157-87-3 (S)-4-(1-isothiocyanato-2-(4-nitrophenyl)ethyl)-2-phenylthiazole 
• 6292-65-5 oxalic acid monohydrazide 
• 293291-20-0 (S)-tert-butyl 4-bromo-1-(4-nitrophenyl)-3-oxobutan-2-ylcarbamate 
• 127106-74-5 (S)-[3-diazo-1-(4-nitrobenzyl)-2-oxo-propyl]carbamic acid tert-butyl ester 
• 960157-85-1 (1S)-2-(4-nitrophenyl)-1-(2-phenyl-1,3-thiazol-4-yl)ethan-1-amine hydrobromide 
• 33305-77-0 Boc-Phe(p-NO₂)-OH 
• 1068-57-1 acetic acid hydrazide 

Downstream Products

• 960157-91-9 (S)-4-[2-(5-methyl-1,3,4-thiadiazol-2-ylamino)-2-(2-phenylthiazol-4-yl)ethyl]phenylsulfamic acid ammonium salt 

Relevant articles and documents

THIADIAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF OCULAR EDEMA

Disclosed are methods for the treatment of diseases or conditions of the eye, especially retinopathies, ocular edema and ocular neovascularization. Non-limiting examples of these diseases or conditions include diabetic macular edema, age-related macular d

METHODS FOR TREATING VASCULAR LEAK SYNDROME

Disclosed are methods for treating Vascular Leak Syndrome. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, inter alia, sepsis, lupus, inflammatory bowel disease. Yet further disclosed are methods for treating rena

METHODS FOR TREATING VASCULAR LEAK SYNDROME

Disclosed are methods for treating Vascular Leak Syndrome. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, inter alia, sepsis, lupus, irritable bowel disease. Yet further disclosed are methods for treating renal c